Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses (2021 - 2025)

Historic Operating Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $2.2 million.

  • InMed Pharmaceuticals' Operating Expenses fell 20.43% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year increase of 925.07%. This contributed to the annual value of $9.7 million for FY2025, which is 382.68% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Operating Expenses stood at $2.2 million, which was down 20.43% from $2.4 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Operating Expenses' 5-year high stood at $6.8 million during Q2 2022, with a 5-year trough of $2.0 million in Q4 2023.
  • Its 5-year average for Operating Expenses is $2.9 million, with a median of $2.4 million in 2025.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 6963.63% in 2023, then soared by 3787.63% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Expenses stood at $4.4 million in 2021, then crashed by 46.99% to $2.3 million in 2022, then dropped by 16.03% to $2.0 million in 2023, then surged by 37.88% to $2.7 million in 2024, then fell by 18.09% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.